Mr. David Elsley reports
CARDIOL THERAPEUTICS' BOARD OF DIRECTORS APPOINTS DR. GUILLERMO TORRE-AMIONE AS CHAIRMAN
Cardiol Therapeutics Inc. has appointed Dr. Guillermo Torre-Amione as chairman. Dr. Torre-Amione has been an independent director of Cardiol since August, 2018, and is taking over from Dr. Eldon Smith, who is the founding chairman of Cardiol and is now retiring from the board.
"I am pleased that Dr. Torre-Amione has agreed to serve as chairman of our board. Dr. Torre-Amione's exceptional knowledge of, and expertise in, both scientific and clinical research in heart failure, including the design and execution of pivotal clinical trials, will provide invaluable leadership and guidance during an exciting period of growth for Cardiol," said David Elsley, president and chief executive officer of Cardiol Therapeutics.
Mr. Elsley continued, "On behalf of Cardiol and the board of directors, I would like to take this opportunity to thank Dr. Eldon Smith for his invaluable contributions to the company as chairman and wish him a healthy and happy well-earned retirement."
Board certified in cardiovascular disease and advanced heart failure/transplant cardiology, Dr. Torre-Amione is a former chief of the heart failure division and a former medical director of cardiac transplantation at the Houston Methodist DeBakey Heart & Vascular Center. He is also: a professor of cardiology at the Methodist Hospital Research Institute, Houston; a professor of medicine at Weill Cornell Medical College of Cornell University, New York; and president of TecSalud, an academic medical centre and medical school of the Instituto Tecnologico y de Estudios Superiores de Monterrey (ITESM) in Mexico.
Dr. Torre-Amione spearheads the Gene and Judy Campbell Laboratory for Cardiac Transplant Research, where his primary areas of research include: heart failure; cardiac transplant; and the role of the immune response in modulating the progression of heart failure. Dr. Torre-Amione initiated a series of clinical studies that led to a United States Food and Drug Administration-approved phase 2 clinical trial of neurostimulation in heart failure, a novel approach to the treatment of patients with advanced heart failure. Other significant clinical investigations include: a study with cardiac transplant patients designed to impact the cardiac hypertrophy that naturally follows transplantation; a protocol for autologous stem cell transfer in patients with advanced refractory heart failure; and a novel study involving plasma exchange in advanced heart failure patients.
After receiving his medical degree from the ITESM in Monterrey, Mexico, Dr. Torre-Amione moved to Chicago, where he conducted graduate studies in immunology that led to a doctorate degree in immunology from the University of Chicago. He then moved to Houston to complete his internship, residency and cardiology fellowship at Baylor College of Medicine, where he received his first academic appointment as a clinical instructor in 1995. Dr. Torre-Amione has published greater than 170 manuscripts in peer-reviewed journals and currently divides his time between his clinical and academic activities in Houston at the Methodist Hospital and in Monterrey, Mexico, at ITESM.
"I am honoured to be appointed chairman of Cardiol and to be given the opportunity to play an important role in the development of this extraordinary company. There is convincing evidence that inflammation plays an important role in the pathogenesis of heart failure and other cardiovascular disorders. Cardiol's therapeutic strategy raises the exciting possibility of delivering an anti-inflammatory treatment to patients with heart failure that is not limited by toxicology concerns. As a cardiologist, I am excited to be part of this groundbreaking research," stated Dr. Torre-Amione.
About Cardiol Therapeutics Inc.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular diseases. The company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a phase 2/3 outcome study in hospitalized patients testing positive for COVID-19. This potentially registrational trial is designed to: (i) evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, cardiovascular disease; and (ii) investigate the influence CardiolRx has on key markers of inflammatory heart disease.
Cardiol is also planning to file an investigational new drug application for a phase 2 international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure, a leading cause of death and hospitalization in North America, with associated annual health care costs in the United States alone exceeding $30-billion.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.